Ranbaxy Remicron MR 30mg Tablet

Ranbaxy Remicron MR 30mg Tablet contains Gliclazide 30mg in a modified-release (MR) formulation, a second-generation sulfonylurea antidiabetic medicine used in the management of type 2 diabetes mellitus. The modified-release design allows the medicine to be released gradually over the day, supporting steady blood glucose control with once-daily dosing for most patients, used alongside diet and exercise as advised by the treating doctor.

Ranbaxy Remicron MR 30mg Tablet is a prescription medicine, and a valid prescription is required before it can be dispensed. It must be prescribed by a registered doctor following assessment of blood glucose control, kidney and liver function, and overall suitability, and can be obtained through DoctorOnCall after an online consultation confirms it is appropriate for the patient.

Gliclazide stimulates the beta cells of the pancreas to release more insulin in response to rising blood glucose, helping to lower blood glucose levels after meals and throughout the day. The modified-release formulation of Remicron MR allows the active ingredient to be released steadily over approximately 24 hours, providing more consistent blood glucose control with a single daily dose compared to immediate-release gliclazide formulations.

Take Ranbaxy Remicron MR 30mg Tablet exactly as prescribed by your doctor, usually once daily with breakfast or the first main meal of the day. Swallow the tablet whole with a glass of water — do not crush or chew it, as this can affect the modified-release mechanism. Do not skip meals after taking this medicine, and do not change your dose without consulting your doctor.

The dose of Ranbaxy Remicron MR 30mg Tablet is individualised by the prescribing doctor based on blood glucose readings and response to treatment, typically started low and adjusted gradually. This medicine requires a valid prescription and should never be started, stopped, or adjusted without medical advice, as incorrect dosing increases the risk of hypoglycaemia or inadequate blood glucose control.

Ranbaxy Remicron MR 30mg Tablet is generally stable for the shelf life stated on the packaging when stored correctly and unopened. Always check the expiry date printed on the carton or blister strip before use, and do not use the tablets after this date.

Store Ranbaxy Remicron MR 30mg Tablet below 30°C in a cool, dry place away from direct sunlight and moisture, in its original packaging. Keep out of reach and sight of children. Do not store in the bathroom or near a sink where humidity is high.

• Known hypersensitivity to gliclazide or other sulfonylureas
• Type 1 diabetes or diabetic ketoacidosis
• Severe kidney or liver impairment
• Severe infection, major surgery, or significant physiological stress requiring insulin therapy instead
• Concurrent use with miconazole (an antifungal medicine)

• Other antidiabetic medicines, insulin, or alcohol can increase the risk of hypoglycaemia when combined with gliclazide
• Certain medicines such as beta-blockers may mask the warning signs of hypoglycaemia
• Miconazole and some other antifungal or antibacterial medicines can significantly increase gliclazide’s blood glucose-lowering effect
• Corticosteroids and some diuretics may raise blood glucose and reduce the medicine’s effectiveness
• Inform your doctor or pharmacist of all other medicines and supplements you are taking

• Take once daily with breakfast and do not skip meals after dosing
• Swallow the tablet whole — do not crush or chew it
• Carry a fast-acting sugar source in case of low blood glucose symptoms such as sweating, shakiness, or confusion
• Attend regular follow-up appointments to monitor blood glucose and organ function
• Limit alcohol intake while on this medicine
• Do not double the dose if you miss one — take the next dose at the usual time

Ranbaxy Remicron MR 30mg Tablet is a prescription medicine, and a valid prescription is required before it can be dispensed. As a modified-release sulfonylurea, it requires ongoing medical supervision because of its hypoglycaemia risk, and patients should be aware of the signs of low blood glucose and know how to respond. Any adjustment to treatment should only be made after consulting a doctor or a DoctorOnCall pharmacist.